Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists : An Analysis of the FAERS Database 2020-2023
© 2024. The Author(s)..
PURPOSE: This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS).
METHODS: A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023. Disproportionality was measured by calculating the reporting odds ratio.
RESULTS: Compared with ipratropium, tiotropium was associated with fewer reports of CV AEs. Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indacaterol or formoterol and umeclidinium with vilanterol significantly reduced reports of CV AEs compared with the respective LAMA. The addition of an ICS to these combinations further reduced the risk of CV AE reports.
CONCLUSION: Our study suggests that inhaled LAMAs are not free from cardiac AE risks. This risk may be more evident when the newer LAMAs are used, but it is generally significantly reduced when COPD patients are treated with dual bronchodilators or triple therapy. However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug's safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:202 |
|---|---|
| Enthalten in: |
Lung - 202(2024), 2 vom: 15. Apr., Seite 119-125 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Matera, Maria Gabriella [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00408-024-00677-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368105342 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368105342 | ||
| 003 | DE-627 | ||
| 005 | 20240425232826.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240207s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00408-024-00677-3 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM368105342 | ||
| 035 | |a (NLM)38321329 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Matera, Maria Gabriella |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists |b An Analysis of the FAERS Database 2020-2023 |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a PURPOSE: This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS) | ||
| 520 | |a METHODS: A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023. Disproportionality was measured by calculating the reporting odds ratio | ||
| 520 | |a RESULTS: Compared with ipratropium, tiotropium was associated with fewer reports of CV AEs. Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indacaterol or formoterol and umeclidinium with vilanterol significantly reduced reports of CV AEs compared with the respective LAMA. The addition of an ICS to these combinations further reduced the risk of CV AE reports | ||
| 520 | |a CONCLUSION: Our study suggests that inhaled LAMAs are not free from cardiac AE risks. This risk may be more evident when the newer LAMAs are used, but it is generally significantly reduced when COPD patients are treated with dual bronchodilators or triple therapy. However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug's safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiovascular adverse events | |
| 650 | 4 | |a Dual bronchodilation | |
| 650 | 4 | |a FAERS | |
| 650 | 4 | |a LAMAs | |
| 650 | 4 | |a Triple therapy | |
| 650 | 7 | |a Tiotropium Bromide |2 NLM | |
| 650 | 7 | |a XX112XZP0J |2 NLM | |
| 650 | 7 | |a Glycopyrrolate |2 NLM | |
| 650 | 7 | |a V92SO9WP2I |2 NLM | |
| 650 | 7 | |a Adrenergic beta-2 Receptor Agonists |2 NLM | |
| 650 | 7 | |a Drug Combinations |2 NLM | |
| 650 | 7 | |a Muscarinic Antagonists |2 NLM | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a Receptors, Muscarinic |2 NLM | |
| 700 | 1 | |a Calzetta, Luigino |e verfasserin |4 aut | |
| 700 | 1 | |a Rogliani, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Hanania, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzola, Mario |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung |d 1976 |g 202(2024), 2 vom: 15. Apr., Seite 119-125 |w (DE-627)NLM000286648 |x 1432-1750 |7 nnns |
| 773 | 1 | 8 | |g volume:202 |g year:2024 |g number:2 |g day:15 |g month:04 |g pages:119-125 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00408-024-00677-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 202 |j 2024 |e 2 |b 15 |c 04 |h 119-125 | ||